 | • レポートコード：MMG23DC12297 • 出版社/出版日：Market Monitor Global / 2023年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、100ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User（1名様閲覧用） | ￥471,250 (USD3,250) | ▷ お問い合わせ |
| Multi User（20名様閲覧用） | ￥612,625 (USD4,225) | ▷ お問い合わせ |
| Enterprise User（閲覧人数制限なし） | ￥706,875 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の細胞&遺伝子治療CDMO市場規模と予測を収録しています。・世界の細胞&遺伝子治療CDMO市場：売上、2018年-2023年、2024年-2029年 ・世界の細胞&遺伝子治療CDMO市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の細胞&遺伝子治療CDMO市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「治験材料用CDMO」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 細胞&遺伝子治療CDMOのグローバル主要企業は、Lonza、 Charles River Laboratories、 Cytiva、 Catalent Biologics、 FUJIFILM Diosynth Biotechnologies、 BioCentriq、 RoslinCT、 Thermo Scientific、 Mesoblast、 Cellularity、 Bluebird Bio、 Editas Medicine、 Andelyn Biosciences、 Wuxi Advanced Therapies、 AGC Biologics、 Pfizer CentreOne、 Almac Group、 PCI Pharma Servicesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、細胞&遺伝子治療CDMOのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の細胞&遺伝子治療CDMO市場：タイプ別、2018年-2023年、2024年-2029年 世界の細胞&遺伝子治療CDMO市場：タイプ別市場シェア、2022年 ・治験材料用CDMO、開発&製造用CDMO、その他 世界の細胞&遺伝子治療CDMO市場：用途別、2018年-2023年、2024年-2029年 世界の細胞&遺伝子治療CDMO市場：用途別市場シェア、2022年 ・製薬会社、バイオテクノロジー会社、その他 世界の細胞&遺伝子治療CDMO市場：地域・国別、2018年-2023年、2024年-2029年 世界の細胞&遺伝子治療CDMO市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における細胞&遺伝子治療CDMOのグローバル売上、2018年-2023年 ・主要企業における細胞&遺伝子治療CDMOのグローバル売上シェア、2022年 ・主要企業における細胞&遺伝子治療CDMOのグローバル販売量、2018年-2023年 ・主要企業における細胞&遺伝子治療CDMOのグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Lonza、 Charles River Laboratories、 Cytiva、 Catalent Biologics、 FUJIFILM Diosynth Biotechnologies、 BioCentriq、 RoslinCT、 Thermo Scientific、 Mesoblast、 Cellularity、 Bluebird Bio、 Editas Medicine、 Andelyn Biosciences、 Wuxi Advanced Therapies、 AGC Biologics、 Pfizer CentreOne、 Almac Group、 PCI Pharma Services ************************************************************* ・調査・分析レポートの概要 細胞&遺伝子治療CDMO市場の定義 市場セグメント 世界の細胞&遺伝子治療CDMO市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の細胞&遺伝子治療CDMO市場規模 世界の細胞&遺伝子治療CDMO市場規模：2022年 VS 2029年 世界の細胞&遺伝子治療CDMO市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの細胞&遺伝子治療CDMOの売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の細胞&遺伝子治療CDMO製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：治験材料用CDMO、開発&製造用CDMO、その他 細胞&遺伝子治療CDMOのタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：製薬会社、バイオテクノロジー会社、その他 細胞&遺伝子治療CDMOの用途別グローバル売上・予測 ・地域別市場分析 地域別細胞&遺伝子治療CDMO市場規模 2022年と2029年 地域別細胞&遺伝子治療CDMO売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Lonza、 Charles River Laboratories、 Cytiva、 Catalent Biologics、 FUJIFILM Diosynth Biotechnologies、 BioCentriq、 RoslinCT、 Thermo Scientific、 Mesoblast、 Cellularity、 Bluebird Bio、 Editas Medicine、 Andelyn Biosciences、 Wuxi Advanced Therapies、 AGC Biologics、 Pfizer CentreOne、 Almac Group、 PCI Pharma Services ... |
This research report provides a comprehensive analysis of the Cell and Gene Therapy CDMO market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Cell and Gene Therapy CDMO market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Cell and Gene Therapy CDMO, challenges faced by the industry, and potential opportunities for market players.
The global Cell and Gene Therapy CDMO market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Cell and Gene Therapy CDMO market presents opportunities for various stakeholders, including Pharmaceutical Company, Biotechnology Company. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Cell and Gene Therapy CDMO market. Additionally, the growing consumer demand present avenues for market expansion.
The global Cell and Gene Therapy CDMO market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Cell and Gene Therapy CDMO market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Cell and Gene Therapy CDMO market.
Market Overview: The report provides a comprehensive overview of the Cell and Gene Therapy CDMO market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Clinical Trial Material CDMOs, Development and Manufacturing CDMOs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Cell and Gene Therapy CDMO market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Cell and Gene Therapy CDMO market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Cell and Gene Therapy CDMO market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Cell and Gene Therapy CDMO market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Cell and Gene Therapy CDMO market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Cell and Gene Therapy CDMO market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Cell and Gene Therapy CDMO, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Cell and Gene Therapy CDMO market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Cell and Gene Therapy CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Clinical Trial Material CDMOs
Development and Manufacturing CDMOs
Other
Market segment by Application
Pharmaceutical Company
Biotechnology Company
Other
Global Cell and Gene Therapy CDMO Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Lonza
Charles River Laboratories
Cytiva
Catalent Biologics
FUJIFILM Diosynth Biotechnologies
BioCentriq
RoslinCT
Thermo Scientific
Mesoblast
Cellularity
Bluebird Bio
Editas Medicine
Andelyn Biosciences
Wuxi Advanced Therapies
AGC Biologics
Pfizer CentreOne
Almac Group
PCI Pharma Services
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cell and Gene Therapy CDMO, market overview.
Chapter 2: Global Cell and Gene Therapy CDMO market size in revenue.
Chapter 3: Detailed analysis of Cell and Gene Therapy CDMO company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cell and Gene Therapy CDMO in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Cell and Gene Therapy CDMO Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cell and Gene Therapy CDMO Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cell and Gene Therapy CDMO Overall Market Size
2.1 Global Cell and Gene Therapy CDMO Market Size: 2022 VS 2029
2.2 Global Cell and Gene Therapy CDMO Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Cell and Gene Therapy CDMO Players in Global Market
3.2 Top Global Cell and Gene Therapy CDMO Companies Ranked by Revenue
3.3 Global Cell and Gene Therapy CDMO Revenue by Companies
3.4 Top 3 and Top 5 Cell and Gene Therapy CDMO Companies in Global Market, by Revenue in 2022
3.5 Global Companies Cell and Gene Therapy CDMO Product Type
3.6 Tier 1, Tier 2 and Tier 3 Cell and Gene Therapy CDMO Players in Global Market
3.6.1 List of Global Tier 1 Cell and Gene Therapy CDMO Companies
3.6.2 List of Global Tier 2 and Tier 3 Cell and Gene Therapy CDMO Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Cell and Gene Therapy CDMO Market Size Markets, 2022 & 2029
4.1.2 Clinical Trial Material CDMOs
4.1.3 Development and Manufacturing CDMOs
4.1.4 Other
4.2 By Type – Global Cell and Gene Therapy CDMO Revenue & Forecasts
4.2.1 By Type – Global Cell and Gene Therapy CDMO Revenue, 2018-2023
4.2.2 By Type – Global Cell and Gene Therapy CDMO Revenue, 2024-2029
4.2.3 By Type – Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Cell and Gene Therapy CDMO Market Size, 2022 & 2029
5.1.2 Pharmaceutical Company
5.1.3 Biotechnology Company
5.1.4 Other
5.2 By Application – Global Cell and Gene Therapy CDMO Revenue & Forecasts
5.2.1 By Application – Global Cell and Gene Therapy CDMO Revenue, 2018-2023
5.2.2 By Application – Global Cell and Gene Therapy CDMO Revenue, 2024-2029
5.2.3 By Application – Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Cell and Gene Therapy CDMO Market Size, 2022 & 2029
6.2 By Region – Global Cell and Gene Therapy CDMO Revenue & Forecasts
6.2.1 By Region – Global Cell and Gene Therapy CDMO Revenue, 2018-2023
6.2.2 By Region – Global Cell and Gene Therapy CDMO Revenue, 2024-2029
6.2.3 By Region – Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Cell and Gene Therapy CDMO Revenue, 2018-2029
6.3.2 US Cell and Gene Therapy CDMO Market Size, 2018-2029
6.3.3 Canada Cell and Gene Therapy CDMO Market Size, 2018-2029
6.3.4 Mexico Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Cell and Gene Therapy CDMO Revenue, 2018-2029
6.4.2 Germany Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.3 France Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.4 U.K. Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.5 Italy Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.6 Russia Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.7 Nordic Countries Cell and Gene Therapy CDMO Market Size, 2018-2029
6.4.8 Benelux Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Cell and Gene Therapy CDMO Revenue, 2018-2029
6.5.2 China Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5.3 Japan Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5.4 South Korea Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5.5 Southeast Asia Cell and Gene Therapy CDMO Market Size, 2018-2029
6.5.6 India Cell and Gene Therapy CDMO Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Cell and Gene Therapy CDMO Revenue, 2018-2029
6.6.2 Brazil Cell and Gene Therapy CDMO Market Size, 2018-2029
6.6.3 Argentina Cell and Gene Therapy CDMO Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Cell and Gene Therapy CDMO Revenue, 2018-2029
6.7.2 Turkey Cell and Gene Therapy CDMO Market Size, 2018-2029
6.7.3 Israel Cell and Gene Therapy CDMO Market Size, 2018-2029
6.7.4 Saudi Arabia Cell and Gene Therapy CDMO Market Size, 2018-2029
6.7.5 UAE Cell and Gene Therapy CDMO Market Size, 2018-2029
7 Cell and Gene Therapy CDMO Companies Profiles
7.1 Lonza
7.1.1 Lonza Company Summary
7.1.2 Lonza Business Overview
7.1.3 Lonza Cell and Gene Therapy CDMO Major Product Offerings
7.1.4 Lonza Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.1.5 Lonza Key News & Latest Developments
7.2 Charles River Laboratories
7.2.1 Charles River Laboratories Company Summary
7.2.2 Charles River Laboratories Business Overview
7.2.3 Charles River Laboratories Cell and Gene Therapy CDMO Major Product Offerings
7.2.4 Charles River Laboratories Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.2.5 Charles River Laboratories Key News & Latest Developments
7.3 Cytiva
7.3.1 Cytiva Company Summary
7.3.2 Cytiva Business Overview
7.3.3 Cytiva Cell and Gene Therapy CDMO Major Product Offerings
7.3.4 Cytiva Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.3.5 Cytiva Key News & Latest Developments
7.4 Catalent Biologics
7.4.1 Catalent Biologics Company Summary
7.4.2 Catalent Biologics Business Overview
7.4.3 Catalent Biologics Cell and Gene Therapy CDMO Major Product Offerings
7.4.4 Catalent Biologics Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.4.5 Catalent Biologics Key News & Latest Developments
7.5 FUJIFILM Diosynth Biotechnologies
7.5.1 FUJIFILM Diosynth Biotechnologies Company Summary
7.5.2 FUJIFILM Diosynth Biotechnologies Business Overview
7.5.3 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Major Product Offerings
7.5.4 FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.5.5 FUJIFILM Diosynth Biotechnologies Key News & Latest Developments
7.6 BioCentriq
7.6.1 BioCentriq Company Summary
7.6.2 BioCentriq Business Overview
7.6.3 BioCentriq Cell and Gene Therapy CDMO Major Product Offerings
7.6.4 BioCentriq Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.6.5 BioCentriq Key News & Latest Developments
7.7 RoslinCT
7.7.1 RoslinCT Company Summary
7.7.2 RoslinCT Business Overview
7.7.3 RoslinCT Cell and Gene Therapy CDMO Major Product Offerings
7.7.4 RoslinCT Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.7.5 RoslinCT Key News & Latest Developments
7.8 Thermo Scientific
7.8.1 Thermo Scientific Company Summary
7.8.2 Thermo Scientific Business Overview
7.8.3 Thermo Scientific Cell and Gene Therapy CDMO Major Product Offerings
7.8.4 Thermo Scientific Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.8.5 Thermo Scientific Key News & Latest Developments
7.9 Mesoblast
7.9.1 Mesoblast Company Summary
7.9.2 Mesoblast Business Overview
7.9.3 Mesoblast Cell and Gene Therapy CDMO Major Product Offerings
7.9.4 Mesoblast Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.9.5 Mesoblast Key News & Latest Developments
7.10 Cellularity
7.10.1 Cellularity Company Summary
7.10.2 Cellularity Business Overview
7.10.3 Cellularity Cell and Gene Therapy CDMO Major Product Offerings
7.10.4 Cellularity Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.10.5 Cellularity Key News & Latest Developments
7.11 Bluebird Bio
7.11.1 Bluebird Bio Company Summary
7.11.2 Bluebird Bio Business Overview
7.11.3 Bluebird Bio Cell and Gene Therapy CDMO Major Product Offerings
7.11.4 Bluebird Bio Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.11.5 Bluebird Bio Key News & Latest Developments
7.12 Editas Medicine
7.12.1 Editas Medicine Company Summary
7.12.2 Editas Medicine Business Overview
7.12.3 Editas Medicine Cell and Gene Therapy CDMO Major Product Offerings
7.12.4 Editas Medicine Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.12.5 Editas Medicine Key News & Latest Developments
7.13 Andelyn Biosciences
7.13.1 Andelyn Biosciences Company Summary
7.13.2 Andelyn Biosciences Business Overview
7.13.3 Andelyn Biosciences Cell and Gene Therapy CDMO Major Product Offerings
7.13.4 Andelyn Biosciences Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.13.5 Andelyn Biosciences Key News & Latest Developments
7.14 Wuxi Advanced Therapies
7.14.1 Wuxi Advanced Therapies Company Summary
7.14.2 Wuxi Advanced Therapies Business Overview
7.14.3 Wuxi Advanced Therapies Cell and Gene Therapy CDMO Major Product Offerings
7.14.4 Wuxi Advanced Therapies Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.14.5 Wuxi Advanced Therapies Key News & Latest Developments
7.15 AGC Biologics
7.15.1 AGC Biologics Company Summary
7.15.2 AGC Biologics Business Overview
7.15.3 AGC Biologics Cell and Gene Therapy CDMO Major Product Offerings
7.15.4 AGC Biologics Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.15.5 AGC Biologics Key News & Latest Developments
7.16 Pfizer CentreOne
7.16.1 Pfizer CentreOne Company Summary
7.16.2 Pfizer CentreOne Business Overview
7.16.3 Pfizer CentreOne Cell and Gene Therapy CDMO Major Product Offerings
7.16.4 Pfizer CentreOne Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.16.5 Pfizer CentreOne Key News & Latest Developments
7.17 Almac Group
7.17.1 Almac Group Company Summary
7.17.2 Almac Group Business Overview
7.17.3 Almac Group Cell and Gene Therapy CDMO Major Product Offerings
7.17.4 Almac Group Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.17.5 Almac Group Key News & Latest Developments
7.18 PCI Pharma Services
7.18.1 PCI Pharma Services Company Summary
7.18.2 PCI Pharma Services Business Overview
7.18.3 PCI Pharma Services Cell and Gene Therapy CDMO Major Product Offerings
7.18.4 PCI Pharma Services Cell and Gene Therapy CDMO Revenue in Global Market (2018-2023)
7.18.5 PCI Pharma Services Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Table 1. Cell and Gene Therapy CDMO Market Opportunities & Trends in Global Market
Table 2. Cell and Gene Therapy CDMO Market Drivers in Global Market
Table 3. Cell and Gene Therapy CDMO Market Restraints in Global Market
Table 4. Key Players of Cell and Gene Therapy CDMO in Global Market
Table 5. Top Cell and Gene Therapy CDMO Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Cell and Gene Therapy CDMO Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Cell and Gene Therapy CDMO Revenue Share by Companies, 2018-2023
Table 8. Global Companies Cell and Gene Therapy CDMO Product Type
Table 9. List of Global Tier 1 Cell and Gene Therapy CDMO Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Cell and Gene Therapy CDMO Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Cell and Gene Therapy CDMO Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Cell and Gene Therapy CDMO Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Cell and Gene Therapy CDMO Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Cell and Gene Therapy CDMO Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Cell and Gene Therapy CDMO Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Cell and Gene Therapy CDMO Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2024-2029
Table 30. Lonza Company Summary
Table 31. Lonza Cell and Gene Therapy CDMO Product Offerings
Table 32. Lonza Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 33. Lonza Key News & Latest Developments
Table 34. Charles River Laboratories Company Summary
Table 35. Charles River Laboratories Cell and Gene Therapy CDMO Product Offerings
Table 36. Charles River Laboratories Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 37. Charles River Laboratories Key News & Latest Developments
Table 38. Cytiva Company Summary
Table 39. Cytiva Cell and Gene Therapy CDMO Product Offerings
Table 40. Cytiva Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 41. Cytiva Key News & Latest Developments
Table 42. Catalent Biologics Company Summary
Table 43. Catalent Biologics Cell and Gene Therapy CDMO Product Offerings
Table 44. Catalent Biologics Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 45. Catalent Biologics Key News & Latest Developments
Table 46. FUJIFILM Diosynth Biotechnologies Company Summary
Table 47. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Product Offerings
Table 48. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 49. FUJIFILM Diosynth Biotechnologies Key News & Latest Developments
Table 50. BioCentriq Company Summary
Table 51. BioCentriq Cell and Gene Therapy CDMO Product Offerings
Table 52. BioCentriq Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 53. BioCentriq Key News & Latest Developments
Table 54. RoslinCT Company Summary
Table 55. RoslinCT Cell and Gene Therapy CDMO Product Offerings
Table 56. RoslinCT Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 57. RoslinCT Key News & Latest Developments
Table 58. Thermo Scientific Company Summary
Table 59. Thermo Scientific Cell and Gene Therapy CDMO Product Offerings
Table 60. Thermo Scientific Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 61. Thermo Scientific Key News & Latest Developments
Table 62. Mesoblast Company Summary
Table 63. Mesoblast Cell and Gene Therapy CDMO Product Offerings
Table 64. Mesoblast Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 65. Mesoblast Key News & Latest Developments
Table 66. Cellularity Company Summary
Table 67. Cellularity Cell and Gene Therapy CDMO Product Offerings
Table 68. Cellularity Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 69. Cellularity Key News & Latest Developments
Table 70. Bluebird Bio Company Summary
Table 71. Bluebird Bio Cell and Gene Therapy CDMO Product Offerings
Table 72. Bluebird Bio Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 73. Bluebird Bio Key News & Latest Developments
Table 74. Editas Medicine Company Summary
Table 75. Editas Medicine Cell and Gene Therapy CDMO Product Offerings
Table 76. Editas Medicine Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 77. Editas Medicine Key News & Latest Developments
Table 78. Andelyn Biosciences Company Summary
Table 79. Andelyn Biosciences Cell and Gene Therapy CDMO Product Offerings
Table 80. Andelyn Biosciences Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 81. Andelyn Biosciences Key News & Latest Developments
Table 82. Wuxi Advanced Therapies Company Summary
Table 83. Wuxi Advanced Therapies Cell and Gene Therapy CDMO Product Offerings
Table 84. Wuxi Advanced Therapies Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 85. Wuxi Advanced Therapies Key News & Latest Developments
Table 86. AGC Biologics Company Summary
Table 87. AGC Biologics Cell and Gene Therapy CDMO Product Offerings
Table 88. AGC Biologics Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 89. AGC Biologics Key News & Latest Developments
Table 90. Pfizer CentreOne Company Summary
Table 91. Pfizer CentreOne Cell and Gene Therapy CDMO Product Offerings
Table 92. Pfizer CentreOne Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 93. Pfizer CentreOne Key News & Latest Developments
Table 94. Almac Group Company Summary
Table 95. Almac Group Cell and Gene Therapy CDMO Product Offerings
Table 96. Almac Group Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 97. Almac Group Key News & Latest Developments
Table 98. PCI Pharma Services Company Summary
Table 99. PCI Pharma Services Cell and Gene Therapy CDMO Product Offerings
Table 100. PCI Pharma Services Cell and Gene Therapy CDMO Revenue (US$, Mn) & (2018-2023)
Table 101. PCI Pharma Services Key News & Latest Developments
List of Figures
Figure 1. Cell and Gene Therapy CDMO Segment by Type in 2022
Figure 2. Cell and Gene Therapy CDMO Segment by Application in 2022
Figure 3. Global Cell and Gene Therapy CDMO Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Cell and Gene Therapy CDMO Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Cell and Gene Therapy CDMO Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Cell and Gene Therapy CDMO Revenue in 2022
Figure 8. By Type - Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 9. By Application - Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 10. By Type - Global Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 12. By Application - Global Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 14. By Region - Global Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 15. By Country - North America Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 16. US Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 20. Germany Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 21. France Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 28. China Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 32. India Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 34. Brazil Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Cell and Gene Therapy CDMO Revenue Market Share, 2018-2029
Figure 37. Turkey Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Cell and Gene Therapy CDMO Revenue, (US$, Mn), 2018-2029
Figure 41. Lonza Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Charles River Laboratories Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Cytiva Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Catalent Biologics Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. FUJIFILM Diosynth Biotechnologies Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. BioCentriq Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. RoslinCT Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Thermo Scientific Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Mesoblast Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Cellularity Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Bluebird Bio Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Editas Medicine Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Andelyn Biosciences Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Wuxi Advanced Therapies Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. AGC Biologics Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Pfizer CentreOne Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Almac Group Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. PCI Pharma Services Cell and Gene Therapy CDMO Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
| 【細胞&遺伝子治療CDMOについて】 細胞&遺伝子治療CDMO（Contract Development and Manufacturing Organization）は、細胞療法および遺伝子治療に特化した契約開発製造機関のことで、製薬企業やバイオテクノロジー企業が新しい治療法を開発する際に必要な製造工程や研究開発を支援します。このようなCDMOは、医薬品の開発プロセスの中で非常に重要な役割を果たしており、特に細胞療法や遺伝子治療は近年急速に進展している分野のため、これらのサービスの需要は高まっています。 CDMOの基本的な役割としては、製薬企業が自社の製品を市場に投入するために必要な製造や開発プロセスを外部の専門機関に委託することが挙げられます。これにより、製薬企業は自社のリソースを開発戦略に集中させることができ、効率的かつ迅速に製品化を進めることが可能になります。 細胞治療の分野では、患者の細胞を用いて疾病を治療する方法が注目されています。例えば、癌治療においては、患者から採取したT細胞を遺伝子改変し、癌細胞を特異的に攻撃する能力を持たせるCAR-T細胞療法が有名です。このような細胞療法は、特に難治性の癌や遺伝性疾患の治療において新たな希望を提供しています。 遺伝子治療は、遺伝子の欠損や異常によって引き起こされる疾患に対して、正常な遺伝子を患者の細胞に導入することによって治療を目指すアプローチです。例えば、遺伝子による酵素補充治療や、遺伝子編集技術を用いた治療などが含まれます。これによって、特定の遺伝病や遺伝子に起因する疾患に対する有効な治療法が開発されています。 CDMOが提供するサービスには、研究開発、プロセス開発、製造、品質管理、規制対応などが含まれます。特に細胞療法や遺伝子治療においては、製造プロセスが非常に複雑であるため、各段階での専門的な知識と技術が求められます。例えば、細胞の培養条件、遺伝子の導入技術、製造環境の管理、さらにはクオリティコントロールまで、全てのステップにおいて高い専門性が必要です。 細胞&遺伝子治療CDMOの特徴としては、まず第一に、最先端の技術を用いた製造能力が挙げられます。これにより、高品質な細胞や遺伝子製品を安定的に供給することが可能となります。また、CDMOは通常、製品の開発から商業生産まで、一貫したサポートを提供するため、クライアントにとっては非常に便利なパートナーとなります。 さらに、CDMOは通常、規制当局による厳しい品質管理基準を遵守する必要があります。これにより、顧客企業は製品が安全で効果的であることを保証することができます。これは、患者に治療を提供する上で不可欠な要素です。 また、柔軟性もCDMOの大きな特徴の一つです。製薬企業のニーズや市場の変化に応じて、迅速に製造スケールを調整することができるため、新しい製品の開発や規模の拡大に対応しやすいメリットがあります。このような柔軟性は、特にスタートアップ企業にとって重要であり、彼らが自社のビジョンを実現するための支援を受ける上でも重要です。 CDMOの種類は多様です。例えば、プロセス開発を専門とするCDMO、細胞培養に特化したCDMO、最終製品の製造を担当するCDMOなどがあります。また、これらのCDMOは、治療分野によっても特化している場合があります。たとえば、オンコロジーに特化したCDMOや、遺伝病に特化したCDMOなどが考えられます。それぞれのCDMOは、特定のニーズに応じたサービスを提供することにより、顧客企業の成功を支援しています。 細胞&遺伝子治療CDMOの用途は多岐にわたります。癌治療、遺伝子疾患のランク、再生医療など、様々な用途に対応する細胞や遺伝子製品が開発されています。これらの用途に応じた専門技術を有するCDMOが、各企業の研究開発をサポートします。これにより、より多くの患者に革新的な治療法を提供することが可能となります。 最後に、細胞＆遺伝子治療CDMOにおける関連技術についても言及することが重要です。例えば、CRISPR/Cas9技術やZinc Finger Nucleasesなど、遺伝子編集技術の発展は、CDMOが提供する遺伝子治療の可能性を大きく広げています。また、細胞培養技術やバイオプロセス工学も重要な関連技術であり、細胞や遺伝子製品の品質を向上させるために必要不可欠です。 これらの進展により、細胞&遺伝子治療CDMOは、今後もますます重要な存在となることでしょう。新しい治療法の開発が続く中で、CDMOは製薬企業にとって欠かせないパートナーとして、その役割を果たし続けることが期待されます。医療の未来を切り開くために、CDMOは今後も多様な取り組みを進めていくことが求められています。これにより、一人でも多くの患者が新しい治療法の恩恵を受けられることを願ってやみません。 |
